Last reviewed · How we verify
3% Menthol
At a glance
| Generic name | 3% Menthol |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Nordic Spirit Pouch Nicotine Pharmacokinetics Abuse Liability (PHASE1)
- Counterpain PXM Versus Diclofenac Versus Piroxicam (PHASE3)
- Assessment of HPHC Exposure in Smokers Switching to THS/TP18 With Different Device Variants (NA)
- Effect of Different E-cigarette Cooling Flavors on Adults' Sensory Experience TCORS 3.0 (NA)
- An Experimental Evaluation of Menthol-Flavored Tobacco Accessories (NA)
- Sex Differences in E-Cigarette Perception (NA)
- The Antiplaque and Antigingivitis Effect of Pure Green Tea Mouth Wash Compared to Placebo and Essential Oils Mouth Washes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 3% Menthol CI brief — competitive landscape report
- 3% Menthol updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI